You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 222 No. 7, November 13, 1972 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Amantadine in Parkinson's Disease

Review of More Than Two Years' Experience

Robert S. Schwab, MD; David C. Poskanzer, MD; Albert C. England, Jr., MD; Robert R. Young, MD

JAMA. 1972;222(7):792-795.


Abstract

Four hundred thirty patients with Parkinson's disease were treated with amantadine hydrochloride alone or in conjunction with other anti-Parkinsonism medications over a 2 1/2-year period. Of 351 patients who took 200 mg a day for 60 days, 64% showed a favorable response to the drug at 60 days and thereafter. Of those patients who received amantadine and levodopa, 79% responded favorably, as compared with 48% in the group who did not receive levodopa. In one half of the patients treated, a decline in the therapeutic efficacy of amantadine was observed between 30 and 60 days. Few side effects were noted even after long periods of administration, and laboratory studies disclosed no consistent significant abnormalities.



Author Affiliations

From the Parkinson's Disease Project and Neurology Service, Massachusetts General Hospital, and Department of Neurology, Harvard Medical School, Boston.; {dagger}Dr. Schwab died April 6, 1972.


Footnotes

Reprint requests to Department of Neurology, Massachusetts General Hospital, Boston 02114 (Dr. Poskanzer).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Amantadine inhibits platelet-activating factor induced clathrin-mediated endocytosis in human neutrophils
Eckels et al.
Am. J. Physiol. Cell Physiol. 2009;297:C886-C897.
ABSTRACT | FULL TEXT  

An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
Olanow et al.
Neurology 2001;56:S1-S88.
FULL TEXT  

Amantadine for Levodopa-Induced Dyskinesias: A 1-Year Follow-up Study
Metman et al.
Arch Neurol 1999;56:1383-1386.
ABSTRACT | FULL TEXT  

Amantadine Inhibits Nicotinic Acetylcholine Receptor Function in Hippocampal Neurons
Matsubayashi et al.
J. Pharmacol. Exp. Ther. 1997;281:834-844.
ABSTRACT | FULL TEXT  

Prevention of Russian Influenza by Amantadine
Monto et al.
JAMA 1979;241:1003-1007.
ABSTRACT  

Control of Influenza in the Hospital
HOFFMAN and DIXON
ANN INTERN MED 1977;87:725-728.
ABSTRACT  

Prevention and Control of Influenza by Chemoprophylaxis and Chemotherapy: Prospects From Examination of Recent Experience
Jackson and Stanley
JAMA 1976;235:2739-2742.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1972 American Medical Association. All Rights Reserved.